Rectum Cancer Clinical Trial
Official title:
Effects of Modified Precision Functional Sphincter-Preserving Surgery (PPS) on Ultralow Rectal Cancer: A Multicenter Prospective Cohort Study
RATIONALE: Colorectal cancer is one of the most common cancers. However, approaches to minimize surgical trauma, preserve anal function, avoid abdominal stoma, and improve quality of life for patients with ultralow rectal cancers were limited. Thus, new technologies are urgently needed to improve the anal preservation rate, reduce the incidence of anastomotic leakage and improve postoperative anal function in patients with ultralow rectal cancer. PURPOSE: This one-arm multicenter prospective cohort study aims to collect the data of patients with ultralow rectal cancer who undergo sphincter-preserving surgeries, including modified PPS and conventional surgeries, then compare the effects of different operations on clinical outcomes and to see the efficacy and safety of modified PPS surgery when compared with conventional procedures in the treatment of ultralow rectal cancer.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | May 1, 2026 |
Est. primary completion date | May 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histological proof of newly diagnosed primary adenocarcinoma of the rectum 2. The lower edge of tumor < 3 cm from the dentate line 3. Clinical T stage = T3 Exclusion Criteria: 1. The lower edge of tumor < 1 cm from the dentate line 2. Locally advanced stage of tumor 3. Presence of metastatic disease or recurrent rectal tumor 4. Concomitant malignancies 5. Concurrent uncontrolled medical conditions 6. Impaired anal function before surgery 7. Presence of acute bowel obstruction or bowel perforation caused by cancer 8. Pregnancy or breast feeding |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Tenth People's Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai 10th People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of temporary defunctioning stoma | The percentage of patients who get temporary defunctioning stoma to limit the consequences of anastomotic leakage. | Within 30 days after operation | |
Primary | The percentage of patients who develop anastomotic leakage | The percentage of patients who develop anastomotic leakage | Within 30 days after operation | |
Primary | Postoperative anal function assessed by Wexner scale | Ranging from 0 (perfect continence) to 20 (complete incontinence) | 2 years since the start of treatment | |
Primary | Postoperative anal function assessed by Vaizey scale | Ranging from 0 (perfect continence) to 24 (complete incontinence) | 2 years since the start of treatment | |
Secondary | Rate of sphincter-preservation rates | The percentage of patients who preserve the anatomical structure of the anus | Within 30 days after operation | |
Secondary | The number of short-term postoperative complications | The number of grade II and higher postoperative complications according to the Clavien-Dindo classification | Within 30 days after operation | |
Secondary | Postoperative hospital stay | The time between the operation date and the discharge date. | Within 30 days after operation | |
Secondary | Hospitalization costs | The total cost of hospitalization | Within 30 days after operation | |
Secondary | 30-Day Readmission Rate | Percentage of readmitted patients within 30 days after operation | Within 30 days after operation | |
Secondary | Disease-free survival | Disease-free survival is defined as the time from surgery to recurrence of tumor or death | Up to 5 years after the last patient recruited | |
Secondary | Overall survival | Overall survival is defined as the time from surgery until death from any cause. | Up to 5 years after the last patient recruited |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT00409994 -
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04371198 -
Patient-Derived Organoids for Rectal Cancer
|
N/A | |
Recruiting |
NCT04916990 -
Improving Care for Rural Patients With Solid Tumors
|
N/A | |
Active, not recruiting |
NCT05305820 -
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
|
N/A | |
Recruiting |
NCT03699761 -
The Role of Pelvic Peritonization in Laparoscopic or Robotic Low Anterior Resection
|
N/A | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT03843957 -
Effectiveness and Implementation of mPATH-CRC
|
N/A | |
Completed |
NCT02423226 -
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
|
Phase 2 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Not yet recruiting |
NCT06066931 -
Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE
|
N/A | |
Recruiting |
NCT02738359 -
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
|
||
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Active, not recruiting |
NCT02458664 -
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
|
N/A | |
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Recruiting |
NCT05715255 -
Adaptive Symptom Self-Management Immunotherapy Study
|
N/A | |
Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
Recruiting |
NCT04405206 -
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
|